Biovail Abandons Wellbutrin Litigation

Law360, New York (March 5, 2007, 12:00 AM EST) -- After years of warring over Wellbutrin, Canadian pharmaceutical company Biovail Corp. has thrown in the towel and agreed to a “comprehensive” settlement with a slew of drugmakers seeking to launch a generic version of the blockbuster antidepressant.

On Monday, Biovail revealed that it had reached an agreement with Anchen Pharmaceuticals LLP, Impax Laboratories Inc., Watson Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. in its long-standing battle over Wellbutrin XL.

Biovail had begun legal proceedings against the companies in 2005 after they filed abbreviated new drug applications...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.